Using targeted lipid nanoparticles to deliver gene therapies for eradicating HIV reservoirs
Targeted lipid nanoparticles for gene therapeutics delivery approach to eradicating HIV reservoirs
This study is exploring a new way to help people with HIV by using tiny particles to deliver special gene treatments directly to the infected cells, aiming to better control the virus and improve health outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11084797 on NIH RePORTER |
What this research studies
This research investigates a novel approach to eliminate HIV reservoirs in the body by using targeted lipid nanoparticles (LNPs) that deliver gene therapies directly to infected cells. The study aims to achieve optimal viral suppression through ultra-long-acting antiretrovirals, followed by the precise delivery of CRISPR-Cas9 technology to excise integrated HIV DNA. By focusing on specific immune cells and tissues, the research seeks to enhance the effectiveness of these therapies and improve patient outcomes. The methodology includes advanced imaging techniques to track the distribution and effectiveness of the treatment in both laboratory settings and animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have not responded adequately to existing antiretroviral therapies.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS with significant immune system damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking method for completely eradicating HIV from the body, potentially transforming the lives of those living with the virus.
How similar studies have performed: While the approach of using lipid nanoparticles for targeted delivery is promising, the specific combination of CRISPR technology and HIV eradication is still largely untested in human subjects.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Gendelman, Howard E — University of Nebraska Medical Center
- Study coordinator: Gendelman, Howard E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.